natgillin/translations-raw huggingface dataset:
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Dobivali so klopidogrel (udarni odmerek 300 mg, nato po 75 mg na dan, n = 1.752) ali placebo (n = 1.739), oboje v kombinaciji z ASA (150–325 mg kot udarni odmerek, nato 75–162 mg na dan), s fibrinolitičnim sredstvom in po potrebi heparinom.
Patients received crizotinib 250 mg orally twice daily.
Bolniki so prejemali krizotinib v odmerku 250 mg peroralno dvakrat na dan.
Patients received different doses of Revestive or standard treatment for 12 weeks.
Bolniki so 12 tednov prejemali različne odmerke zdravila Revestive ali standardno zdravljenje.
Patients received doses ranging from 30 to 60 Units/kg (median dose
Bolniki so prejemali velaglucerazo alfa v odmerkih od 30 do 60 enot/kg (mediana odmerka
Patients received drotrecogin alfa (activated) within 48 hours of onset of the first sepsis- induced organ dysfunction.
Bolniki so drotrekogin alfa (aktiviran) prejeli v 48 urah po pojavu prve motnje delovanja organov, povzročene s sepso.
Patients received either 75 mg alirocumab Q2W or placebo in addition to their existing lipid-modifying therapy.
Bolniki so poleg že uporabljanjega zdravljenja za prilagoditev lipidov prejemali ali alirokumab v odmerku 75 mg na 2 tedna ali placebo.
Patients received either Arzerra as monthly intravenous infusions (Cycle 1: 300 mg on day 1 and 1,000 mg on day 8.
Bolniki so prejemali ali zdravilo Arzerra v intravenskih infuzijah vsak mesec (1. ciklus: 300 mg 1. dan in 1.000 mg 8. dan.
Patients received either lumacaftor/ivacaftor (n=62) or placebo (n=63) in addition to their prescribed CF therapies.
Bolniki so poleg svojih predpisanih terapij CF prejemali bodisi lumakaftor/ivakaftor (n=62) ali placebo (n=63).
Patients received either placebo or Rebif (44 micrograms given once or three times a week) for two years.
Bolniki so dve leti prejemali bodisi placebo bodisi zdravilo Rebif (44 mikrogramov enkrat ali trikrat na teden).
Patients received either Rebif (22 or 44 micrograms) or placebo (a dummy treatment) for two years.
Dve leti so prejemali bodisi zdravilo Rebif (22 ali 44 mikrogramov) bodisi placebo (zdravilo brez zdravilne učinkovine).
Patients received either Remsima or Remicade in addition to methotrexate for 30 weeks.
Bolniki so 30 tednov prejemali bodisi zdravilo Remsima bodisi Remicade skupaj z metotreksatom.
Patients received either travoprost 0.004% once daily or timolol 0.5% (or 0.25% for subjects younger than 3 years old) twice daily.
Bolniki so prejemali bodisi travoprost 0,004% enkrat na dan ali pa timolol 0,5% (oziroma 0,25% pri preiskovancih, mlajših od 3 let) dvakrat na dan.
Patients received either zoledronic acid 4 mg or placebo every four weeks for one year.
Bolnice so v obdobju enega leta prejemale bodisi 4 mg zoledronske kisline bodisi placebo vsake štiri tedne.
Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1- 0.4 mg/kg weekly (up to 25 mg).
Bolniki so prejemali zdravilo Humira v odmerkih 0,8 mg/kg vsak drugi teden (do največ 40 mg), 0,4 mg/kg vsak drugi teden (do največ 20 mg) ali 0,1 – 0,4 mg/kg metotreksata na teden (do največ 25 mg).
Patients received meningococcal vaccination prior to receipt of Soliris or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.
Pred prejemom zdravila Soliris so bili bolniki cepljeni proti meningokokom ali pa so prejemali ustrezno antibiotično profilakso z ustreznim antibiotikom, dokler ne mineta 2 tedna po cepljenju.
Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter.
Bolniki so prejemali bodisi placebo, infliksimab v odmerku 3 mg/kg ali infliksimab v odmerku 10 mg/kg v tednih 0, 2 in 6, potem pa na vsake 4 tedne do 8 tednov.
Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) for 16 weeks.
Bolniki so dobivali placebo, začetni odmerek 7,5 mg metotreksata z nadaljnjim povečevanjem odmerka do 12. tedna; do največjega odmerka 25 mg, ali začetni odmerek 80 mg zdravila Humira in potem 40 mg vsak drugi teden (začenši en teden po začetnem odmerku) 16 tednov.
Patients received up to 7 treatments at intervals no more frequently than approximately every 6 months.
Bolniki so prejeli do 7 zdravljenj v razmikih, ki niso bili pogostješi od približno 6 mesecev.
Patients receiving any concomitant treatment containing bupropion or naltrexone
Bolniki, ki se sočasno zdravijo s kakršnim koli zdravilom, ki vsebuje bupropion ali naltrekson
Patients receiving bosutinib should have liver function tests prior to treatment initiation and monthly for the first three months of treatment, and as clinically indicated.
Bolniki, ki prejemajo bosutinib, morajo opraviti teste delovanja jeter, in sicer pred začetkom zdravljenja, enkrat na mesec v prvih 3 mesecih zdravljenja, potem pa kot je klinično indicirano.
Patients receiving BRINAVESS have a higher incidence of converting to atrial flutter within the first 2 hours post-dose.
Med bolniki, ki prejmejo zdravilo BRINAVESS, je večja pojavnost prehoda v atrijsko undulacijo v prvih 2 urah po odmerku.
Patients receiving CellCept should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.
Bolnikom, ki prejemajo zdravilo CellCept, je treba naročiti, da morajo takoj poročati o kakršnem koli znaku okužbe, nepričakovani modrici, krvavitvi ali drugih znakih depresije kostnega mozga.
Patients receiving concomitant administration of monoamine oxidase inhibitors (MAOI).
Bolniki, ki sočasno prejemajo zaviralce monoaminooksidaze (MAO).
Patients receiving concomitant non-liposomal irinotecan and CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine have substantially reduced exposure to irinotecan (AUC reduction by 12% with St John’s wort, 57%-79% with phenytoin, phenobarbital, or carbamazepine) and SN-38 (AUC reduction by 42% with St John’s wort, 36%-92% with phenytoin phenobarbital, or carbamazepine).
Bolniki, ki sočasno prejemajo neliposomski irinotekan in antikonvulzive, ki inducirajo encim CYP3A4, tj. fenitoin, fenobarbital ali karbamazepin, imajo bistveno zmanjšano izpostavljenost irinotekanu (zmanjšanje AUC s šentjanževko za 12 % in s fenitoinom, fenobarbitalom in karbamazepinom za 57 – 79 %) in SN-38 (zmanjšanje AUC s šentjanževko za 42 % in s fenitoinom, fenobarbitalom in karbamazepinom za 36–92 %).
Patients receiving concomitant non-liposomal irinotecan and ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased SN-38 exposure by 109%.
Bolniki, ki sočasno prejemajo neliposomski irinotekan in ketokonazol, zaviralec encimov CYP3A4 in UGT1A1, imajo povečano izpostavljenost SN-38 za 109 %.
Patients receiving concomitant potent CYP3A4 inducers may require an increased Votubia dose to achieve the same exposure as patients not taking potent inducers.
Pri bolnikih, ki sočasno prejemajo močne induktorje CYP3A4, so lahko potrebni višji odmerki zdravila Votubia za enako izpostavljenost zdravilu kot pri bolnikih, ki ne prejemajo močnih induktorjev.
Patients receiving concomitant treatment with anticoagulants (e.g. warfarin, acenocoumarole) may be periodically monitored by complete blood counts (platelets), coagulation factors (PT/INR) and physical examination.
Pri bolnikih, ki se sočasno zdravijo z antikoagulanti (npr. varfarin, acenokumarol), se lahko redno spremlja celotna krvna slika (trombociti), koagulacijski faktorji (PČ/INR) in opravi telesni pregled.
Patients receiving concomitant treatment with substances that are potent inhibitors of CYP2D6 or moderate inhibitors of CYP3A4
Bolniki, ki se sočasno zdravijo s snovmi, ki so močni zaviralci CYP2D6 ali zmerni zaviralci CYP3A4
Patients receiving Cosentyx may receive concurrent inactivated or non-live vaccinations.
Bolniki, ki prejemajo zdravilo Cosentyx, so lahko sočasno cepljeni z inaktiviranimi ali drugimi cepivi, ki niso živa.
Patients receiving DepoCyte should be concurrently treated with corticosteroids (e.g. dexamethasone) to mitigate the symptoms of arachnoiditis (see section 4.8), which is a very common adverse reaction.
Bolnike, ki prejemajo zdravilo DepoCyte, morate istočasno zdraviti s kortikosteroidi (npr. z deksametazonom), da ublažite simptome arahnitisa, ki je zelo pogosta neželena reakcija (glejte poglavje 4.8).
Patients receiving dialysis are subject to certain risks for infection specific to dialysis modality.
Bolniki na dializi so izpostavljenih nekaterim tveganjem za okužbe, ki so odvisne od načina dialize, ki jo prejemajo.
Patients receiving Empliciti in combination with lenalidomide should adhere to the pregnancy prevention programme of lenalidomide.
Bolniki, ki prejemajo zdravilo Empliciti v kombinaciji z lenalidomidom, se morajo držati programa za preprečevanje nosečnosti, ki je predviden pri uporabi lenalidomida.
Patients receiving enzalutamide demonstrated a significantly higher total PSA response rate (defined as a ≥ 50% reduction from baseline), compared with patients receiving placebo, 78.0% versus 3.5% (difference = 74.5%, p < 0.0001).
Pri bolnikih, ki so dobivali enzalutamid, je bila dokazana značilno višja skupna stopnja odziva PSA (opredeljeno kot ≥ 50 % zmanjšanje od izhodišča), v primerjavi z bolniki, ki so dobivali placebo, 78,0 % v primerjavi s 3,5 % (razlika = 74,5 %; p < 0,0001).
Patients receiving Epclusa concomitantly with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for tenofovir-associated adverse reactions.
Bolnike, ki prejemajo zdravilo Epclusa sočasno z elvitegravirjem/kobicistatom/emtricitabinom/dizoproksiltenofovirijevim fumaratom ali z dizoproksiltenofovirijevim fumaratom in okrepljenim zaviralcem proteaze HIV, je treba spremljati za pojav s tenofovirjem povezanih neželenih reakcij.
Patients receiving Esbriet should have their liver function checked before and regularly during treatment.
Pri bolnikih, ki se zdravijo z zdravilom Esbriet, je treba pred začetkom zdravljenja in med njim preverjati delovanje jeter.
Patients receiving factor VIII products may sometimes develop antibodies to factor VIII (also known as factor VIII inhibitors), which may prevent the factor VIII product from working properly.
Pri bolnikih, ki prejemajo zdravila, ki vsebujejo faktor VIII, se lahko včasih razvijejo protitelesa proti faktorju VIII (imenujemo jih tudi inhibitorji faktorja VIII), ki lahko faktorju VIII v zdravilu preprečijo pravilno delovanje.
Patients receiving Harvoni concomitantly with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for tenofovir- associated adverse reactions.
Bolnike, ki prejemajo zdravilo Harvonisočasno z elvitegravirjem/kobicistatom/emtricitabinom/dizoproksiltenofovirat fumaratomali s dizoproksiltenofoviratom fumaratom in okrepljenim zaviralcem proteaze HIV, je treba spremljati za pojav s tenofovirjem povezanih neželenih učinkov.
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myfenax, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
Bolniki, ki prejemajo kombinacije imunosupresivnih zdravil, vključno z zdravilom Myfenax, so izpostavljeni povečanem tveganju nastanka limfomov in drugih malignih sprememb, zlasti kožnih (glejte poglavje 4.8).
Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
Bolnike, ki prejemajo imunosupresive, bolj ogroža pojav malignomov.
Patients receiving Incruse had a higher percentage of days when no rescue medication was needed (on average 31.1%) compared with placebo (on average 21.7%).
Bolniki, ki so dobivali zdravilo Incruse so imeli večji odstotek dni brez potrebe po rešilnem zdravilu (povprečno 31,1 %) v primerjavi s placebom (povprečno 21,7 %).
Patients receiving insulin or oral hypoglycaemic medicinal products may require dose reduction of these active substances due to the effect of pegvisomant on insulin sensitivity (see section 4.4).
Pri bolnikih, ki dobivajo insulin ali peroralne antidiabetike, utegne biti potrebno zmanjšanje odmerka teh zdravilnih učinkovin, ker pegvisomant spremeni občutljivost za insulin (glejte poglavje 4.4).
Patients receiving ITP therapy at baseline (n)
Bolniki, ki so se v izhodišču že zdravili zaradi ITP (n)
Patients receiving ledipasvir/sofosbuvir concomitantly with tenofovir disoproxil and a boosted HIV protease inhibitor should be monitored for adverse reactions related to tenofovir disoproxil.
Pri bolnikih, ki prejemajo ledipasvir/sofosbuvir sočasno z dizoproksiltenofoviratom in okrepljenim zaviralcem proteaze HIV, je treba spremljati možne neželene učinke, povezane z dizoproksiltenofoviratom.
Patients receiving ledipasvir/sofosbuvir concomitantly with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for adverse reactions related to tenofovir disoproxil fumarate.
Bolnike, ki prejemajo ledipasvir/sofosbuvir sočasno z dizoproksiltenofovirijevim fumaratom in okrepljenim zaviralcem proteaze HIV, je treba spremljati glede neželenih reakcij, ki so povezane z dizoproksiltenofovirijevim fumaratom.
Patients receiving ledipasvir/sofosbuvir concomitantly with tenofovir disoproxil fumarate and a boosted HIV protease inhibitor should be monitored for adverse reactions related to tenofovir disoproxil fumarate.
Pri bolnikih, ki prejemajo ledipasvir/sofosbuvir sočasno z dizoproksiltenofovirijevim fumaratom in okrepljenim zaviralcem proteaze HIV, je treba spremljati možne neželene učinke, povezane z dizoproksiltenofovirijevim fumaratom.
Patients receiving liraglutide in combination with a sulfonylurea or a basal insulin may have an increased risk of hypoglycaemia (see section 4.8).
Bolniki, ki dobivajo liraglutid skupaj s sulfonilsečnino ali bazalnim insulinom, imajo lahko večje tveganje za hipoglikemijo (glejte poglavje 4.8).
Patients receiving medicinal products of either a narrow therapeutic ratio or medicinal products that require careful clinical monitoring should be followed closely, especially at the time of initiation of lixisenatide treatment.
Bolnike, ki prejemajo zdravila, ki imajo bodisi ozko terapevtsko razmerje ali zahtevajo skrbno klinično spremljanje, je treba bolnika natančno spremljati, zlati v času uvedbe zdravljenje z liksisenatidom.
Patients receiving medicinal products that may affect renal function:
Bolniki, ki prejemajo zdravila, ki lahko vplivajo na ledvično funkcijo:
Patients receiving methadone and Atripla concomitantly should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.
Bolnike, ki sočasno prejemajo metadon in zdravilo Atripla, je treba spremljati zaradi morebitnih odtegnitvenih znakov in jim povečati odmerek metadona, v kolikor je to potrebno.
Patients receiving monoamine oxidase (MAO) inhibitor therapy (see section 4.5)
Zdravljenje z zaviralci monoaminooksidaze (MAO) (glejte poglavje 4.5).
Patients receiving MTX who achieved a PASI 50 response at Week 8 and/or 12 did not receive further dose increases.
Bolnikom, ki so dobivali metotreksat in so 8. in/ali 12. teden dosegli odziv PASI  50, odmerka niso več povečevali.
Patients receiving multiple medications with effects on different central nervous system (CNS) pathways (e.g. antidepressants, neuroleptics, anticholinergics) may be at greater risk of developing NMS.
Bolniki, ki jemljejo več zdravil z učinki na različne poti v centralnem živčnem sistemu (CŽS) (npr. antidepresive, nevroleptike, antiholinergike), so verjetno izpostavljeni večjemu tveganju za razvoj
Patients receiving Myfenax should be monitored for neutropenia, which may be related to Myfenax itself, concomitant medicinal products, viral infections, or some combination of these causes.
Bolnike, ki prejemajo zdravilo Myfenax, je treba skrbno nadzorovati zaradi nevtropenije, ki je lahko posledica jemanja zdravila Myfenax, sočasno uporabljenih zdravil, virusnih okužb ali nekaterih kombinacij teh vzrokov.
Patients receiving Myocet were less likely to experience heart problems than those receiving standard doxorubicin.
Pri bolnicah, ki so prejemale Myocet, je bila verjetnost težav s srcem manjša kot pri tistih, ki so prejemale standardni doksorubicin.
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricaemia in patients at risk for tumour lysis syndrome.
Pri bolnikih, ki prejemajo nelarabin, priporočamo intravensko dovajanje tekočine v skladu z običajno zdravniško prakso preprečevanja hiperurikemije pri bolnikih s tveganjem za pojav sindroma tumorske lize.
Patients receiving olaratumab and doxorubicin are at risk of haemorrhagic events (see section 4.8).
Bolnike, ki prejemajo olaratumab in doksorubicin, ogrožajo hemoragični dogodki (glejte poglavje 4.8).
Patients receiving opioid analgesics
Bolniki, ki prejemajo opioidne analgetike
Patients receiving oral concomitant medicinal products requiring titration or with a narrow therapeutic index should be monitored closely due to potential increased absorption (see section 4.5).
Bolnike na sočasnem zdravljenju z drugimi peroralnimi zdravili, ki zahtevajo titracijo ali imajo ozek terapevtski indeks, je treba skrbno nadzorovati zaradi možnosti povečane absorpcije (glejte poglavje 4.5).
Patients receiving other oral hypoglycaemic medicinal products
Bolniki, ki dobivajo druge peroralne antidiabetike
Patients receiving Pelzont, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9 % were also taking ezetimibe [10 mg].
Bolniki, ki so dobivali zdravilo Pelzont, nikotinsko kislino (pripravek s podaljšanim sproščanjem), ali placebo, so jemali tudi statine (29 % atorvastatin [5–80 mg], 54 % simvastatin [10-80 mg], 17 % druge statine [2,5–180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)) in 9 % od teh jih je jemalo tudi ezetimib [10 mg].
Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential white cell count (WCC) and platelet count.
Bolnikom, ki prejemajo pemetreksed, se mora pred vsakim odmerkom odvzeti kri za popolno krvno sliko, vključno z diferencialno belo krvno sliko (WCC – white cell count) in številom trombocitov.
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45 %, v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini, zdravljeni s pioglitazonom.
Patients receiving placebo + MTX were switched to Simponi 50 mg + MTX after week 24.
Bolniki, ki so prejemali placebo in metotreksat, so po 24. tednu prešli na zdravljenje z zdravilom Simponi 50 mg in metotreksatom.
Patients receiving pomalidomide in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident).
Pri bolnikih, ki so prejemali pomalidomid v kombinaciji z deksametazonom, so se razvili venski trombembolični dogodki (zlasti globoka venska tromboza in pljučna embolija) in arterijski trombotični dogodki (miokardni infarkt in cerebrovaskularni dogodek).
Patients receiving regorafenib who experienced disease progression and for whom in the investigator’s opinion, treatment with regorafenib was providing clinical benefit, were offered the opportunity to continue open-label regorafenib.
Bolniki, ki so prejemali regorafenib, pri katerih je bolezen napredovala in katerim je, po mnenju raziskovalca, zdravljenje z regorafenibom klinično koristilo, je bila ponujena možnost, da nadaljujejo zdravljenje z regorafenibom.
Patients receiving repeated blood transfusions.
Bolniki, ki večkrat prejmejo transfuzijo krvi.
Patients receiving Simponi should be monitored closely for signs and symptoms of active tuberculosis, including patients who tested negative for latent tuberculosis, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection.
Bolnike, ki prejemajo zdravilo Simponi, vključno z bolniki z negativnimi testi za latentno tuberkulozo, bolniki, ki se zdravijo za latentno tuberkulozo, ali bolniki, ki so bili predhodno zdravljeni za okužbo s tuberkulozo, je treba pozorno spremljati glede znakov in simptomov aktivne tuberkuloze.
Patients receiving Simulect must be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources, including medications for the treatment of severe hypersensitivity reactions.
Bolniki, ki dobivajo Simulect, se morajo zdraviti v ustanovah, ki imajo ustrezne laboratorijske in podporne medicinske kapacitete s potrebno opremo in osebjem, vključno z zdravili za zdravljenje težkih preobčutljivostnih reakcij.
Patients receiving sirolimus, nifedipine or itraconazole in combination with Mycamine should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary (see section 4.4).
Bolnike, ki prejemajo sirolimus, nifedipin ali itrakonazol v kombinaciji z zdravilom Mycamine, je treba spremljati zaradi možnosti pojava toksičnosti sirolimusa, nifedipina ali itrakonazola ter po potrebi zmanjšati njihove odmerke (glejte poglavje 4.4).
Patients receiving sirolimus, nifedipine or itraconazole in combination with Mycamine should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary (see section 4.5).
Bolnike, ki prejemajo sirolimus, nifedipin ali itrakonazol v kombinaciji z zdravilom Mycamine, je potrebno spremljati zaradi možnosti pojava toksičnosti sirolimusa, nifedipina ali itrakonazola in po potrebi zmanjšati odmerke sirolinusa, nifedipina ali itrakonusa (glejte poglavje 4.5).
Patients receiving sirolimus, nifedipine or itraconazole in combination with Mycamine should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary.
Bolnike, ki prejemajo sirolimus, nifedipin ali itrakonazol v kombinaciji z zdravilom Mycamine, je treba spremljati zaradi možnosti pojava toksičnosti sirolimusa, nifedipina ali itrakonazola ter po potrebi zmanjšati njihove odmerke.
Patients receiving STELARA may receive concurrent inactivated or non-live vaccinations.
Bolniki, ki prejemajo zdravilo STELARA, lahko v tem času prejmejo tudi inaktivirana ali mrtva cepiva.
Patients receiving Stribild concomitantly with ledipasvir/sofosbuvir should be monitored for adverse reactions related to tenofovir disoproxil fumarate.
Bolnike, ki prejemajo zdravilo Stribild sočasno z ledipasvirjem/sofosbuvirjem, je treba spremljati glede neželenih reakcij, ki so povezane z dizoproksiltenofovirijevim fumaratom.
Patients receiving systemic steroid therapy, clonidine and H2 blocking agents.
Bolniki, zdravljeni s sistemskimi steroidi, klonidinom ali antagonisti histaminskih receptorjev H2.
Patients receiving Tecfidera should be instructed to report symptoms of infections to a physician.
Bolnikom, ki prejemajo zdravilo Tecfidera, je treba naročiti, da zdravniku poročajo o simptomih okužb.